Baxter International (MEX:BAX) Cyclically Adjusted PS Ratio: 0.78 (As of Jul. 11, 2026) — 71% Below Median


MEX:BAX Baxter International Inc MEX:BAX
44 GF Score
Price MXN368.00
GF Value MXN559.81
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Baxter International Cyclically Adjusted PS Ratio?

Baxter International MEX:BAX 44 Cyclically Adjusted PS Ratio is 0.78 as of Jul. 11, 2026, which is 71% below its 10-year median of 2.68. GuruFocus rates MEX:BAX with a GF Score™ of 44/100 and a GF Value™ of MXN559.81 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 523 Medical Devices & Instruments companies, Baxter International ranks better than 73.8% on this metric.

As of today (2026-07-11), Baxter International's current share price is MXN368.00. Baxter International's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN473.49. Baxter International's Cyclically Adjusted PS Ratio for today is 0.78.

The historical rank and industry rank for Baxter International's Cyclically Adjusted PS Ratio or its related term are showing as below:

MEX:BAX' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.63   Med: 2.68   Max: 4.06
Current: 0.88

During the past years, Baxter International's highest Cyclically Adjusted PS Ratio was 4.06. The lowest was 0.63. And the median was 2.68.

MEX:BAX's Cyclically Adjusted PS Ratio is ranked better than
73.8% of 523 companies
in the Medical Devices & Instruments industry
Industry Median: 2.32 vs MEX:BAX: 0.88

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Baxter International's adjusted revenue per share data for the three months ended in Mar. 2026 was MXN94.575. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN473.49 for the trailing ten years ended in Mar. 2026.

Shiller PE for Stocks: The True Measure of Stock Valuation


Baxter International  (MEX:BAX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Baxter International Cyclically Adjusted PS Ratio Related Terms


Baxter International Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Baxter International's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Baxter International Cyclically Adjusted PS Ratio Chart

Baxter International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.58 2.10 1.53 1.17 0.76

Baxter International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.36 1.20 0.90 0.76 0.65

MEX:BAX vs ALGN, SOLV, COO: Cyclically Adjusted PS Ratio Comparison

For the Medical Instruments & Supplies subindustry, Baxter International's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baxter International Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Baxter International's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Baxter International's Cyclically Adjusted PS Ratio falls into.


MEX:BAX
44GF Score
Baxter International Inc MEX:BAX
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Baxter International Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Baxter International's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=368.00/473.49
=0.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Baxter International's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Baxter International's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=94.575/330.2130*330.2130
=94.575

Current CPI (Mar. 2026) = 330.2130.

Baxter International Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 86.448 241.018 118.440
201609 89.764 241.428 122.775
201612 99.511 241.432 136.104
201703 84.577 243.801 114.554
201706 84.843 244.955 114.373
201709 88.199 246.819 117.999
201712 98.444 246.524 131.863
201803 88.266 249.554 116.795
201806 102.091 251.989 133.783
201809 94.587 252.439 123.728
201812 103.011 251.233 135.395
201903 98.031 254.202 127.344
201906 104.890 256.143 135.222
201909 108.239 256.759 139.204
201912 111.077 256.974 142.735
202003 127.328 258.115 162.894
202006 121.348 257.797 155.435
202009 126.746 260.280 160.801
202012 122.392 260.474 155.161
202103 117.846 264.877 146.915
202106 121.157 271.696 147.251
202109 131.093 274.310 157.809
202112 116.828 278.802 138.371
202203 145.010 287.504 166.551
202206 142.331 296.311 158.616
202209 144.038 296.808 160.249
202212 -27.071 296.797 -30.119
202303 125.390 301.836 137.178
202306 125.598 305.109 135.932
202309 88.942 307.789 95.422
202312 90.023 306.746 96.910
202403 81.029 312.332 85.668
202406 96.584 314.175 101.514
202409 103.797 315.301 108.706
202412 111.922 315.605 117.102
202503 104.480 319.799 107.882
202506 102.938 322.561 105.380
202509 101.179 324.800 102.865
202512 104.384 324.054 106.368
202603 94.575 330.213 94.575

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

What does a Cyclically Adjusted PS Ratio of 0.78 mean?
Baxter International (MEX:BAX) has a Cyclically Adjusted PS Ratio of 0.78 as of Jul. 11, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Baxter International and its competitors. This is 71% below median its historical median of 2.68. Over the past decade, Baxter International's Cyclically Adjusted PS Ratio has ranged from 0.63 to 4.06. According to the industry distribution chart, Baxter International ranks #137 out of 523 companies in the Medical Devices & Instruments industry, placing it in the top 26.2%.
Is Baxter International's Cyclically Adjusted PS Ratio too high?
Baxter International's current Cyclically Adjusted PS Ratio of 0.78 is 71% below median its 10-year median of 2.68. Over the past 10 years, this metric has ranged from a low of 0.63 to a high of 4.06. The Medical Devices & Instruments industry median Cyclically Adjusted PS Ratio is 2.32. Baxter International's value of 0.78 is 66.4% below this industry median. Based on the distribution chart, Baxter International ranks #137 out of 523 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Baxter International has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Baxter International's Cyclically Adjusted PS Ratio compare to ALGN and SOLV?
According to the Medical Devices & Instruments industry distribution chart, Baxter International ranks #137 out of 523 companies for Cyclically Adjusted PS Ratio. This puts Baxter International in the upper half of its industry. The industry median Cyclically Adjusted PS Ratio is 2.32. Baxter International's value of 0.78 is 66.4% below this benchmark. Historically, Baxter International's own Cyclically Adjusted PS Ratio has ranged from 0.63 to 4.06 over the past decade. While the company's 10-year median is 2.68 vs. the industry median of 2.32, Baxter International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Medical Devices & Instruments company?
The median Cyclically Adjusted PS Ratio among Medical Devices & Instruments companies is 2.32, based on 523 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Baxter International's current Cyclically Adjusted PS Ratio of 0.78 is 66.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Baxter International and its competitors. For the Medical Devices & Instruments industry, the median Cyclically Adjusted PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Baxter International's current Cyclically Adjusted PS Ratio is 0.78, which is 71% below median its own 10-year median of 2.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baxter International stock overvalued right now?
Based on GuruFocus' analysis, Baxter International (MEX:BAX) is currently considered Possible Value Trap. The stock's GF Value™ is MXN559.81, compared to a current price of MXN368.00 — trading 34.3% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 0.78, which is 71% below median its 10-year median of 2.68 and 66.4% below the Medical Devices & Instruments industry median of 2.32. Baxter International's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Baxter International (MEX:BAX), the current Cyclically Adjusted PS Ratio is 0.78 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Baxter International (MEX:BAX) Overvalued in 2026?

Based on GuruFocus' analysis, Baxter International stock appears to be undervalued. The current stock price of MXN368.00 is trading 34.3% below its estimated GF Value™ of MXN559.81. GuruFocus considers Baxter International to be Possible Value Trap.

Key valuation signals for MEX:BAX:

  • Cyclically Adjusted PS Ratio: 0.78 (71% below median its 10-year median of 2.68)
  • GF Value™: MXN559.81 vs. price of MXN368.00 (34.3% below fair value)
  • GF Score™: 44/100 with 7 warning signs
  • Industry Position: 66.4% below the Medical Devices & Instruments median (#137 of 523)

No single metric tells the full story. See the MEX:BAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Baxter International Business Description

Address One Baxter Parkway, Deerfield, IL, USA, 60015
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
44GF Score

Get the complete analysis for MEX:BAX

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN368.00
Price
MXN559.81
GF Value